한글목차

세계 종양 분야 단클론항체 시장 규모는 2025년 1,293억 달러에서 2025-2030년 예측 기간 동안 12%의 CAGR을 기록하며 2030년 말까지 2,280억 달러에 달할 것으로 예상됩니다.

북미 시장은 2025년 745억 달러에서 2025-2030년 예측 기간 동안 12.2%의 CAGR로 성장하여 2030년 말까지 1,322억 달러에 달할 것으로 예상됩니다.

유럽 시장은 2025년 292억 달러에서 2030년 말까지 507억 달러에 달할 것으로 예상됩니다. 예측 기간 동안 CAGR 11.7%를 기록할 것으로 예상됩니다.

세계의 종양 분야 단클론항체 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 기술 동향, 법·규제 환경, 시장 규모 추정 및 예측, 각종 부문별·지역별 상세 분석, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 주요 요약

• 시장 전망
• 조사 범위
• 시장 요약
• 시장 역학 및 성장 요인
• 신기술
• 부문 분석
• 지역 분석
• 결론

제2장 시장 개요

• 개요
• 거시경제 요인 분석
• 미국 관세가 제약 산업에 미치는 영향
• 의료비
• 고령화 사회
• 지정학적 리스크, 무역전쟁, 공급망 붕괴, 공급망 혼란
• 세계 경제 성장(GDP)이 제약 부문에 미치는 영향
• Porter's Five Forces 분석

제3장 시장 역학

• 시장 역학
• 시장 촉진요인
• 암 발생률 가속화
• 종양 분야에서의 미충족 수요와 단클론항체의 역할
• 기업의 연구개발비 증가
• 정부 자금 및 의약품 연구개발비 증가
• 시장 억제요인
• 단클론항체의 높은 비용
• 독점성 상실과 제네릭화
• 종양 전문의 부족
• 시장 기회
• 종양 분야에서의 단클론항체의 가능성
• 신흥시장

제4장 규제 현황

• 개요
• 미국
• 유럽
• 아시아태평양

제5장 신기술, 임상시험 분석, 특허 분석

• 개요
• AI
• 면역요법과 세포 치료
• 신흥 바이오마커
• 임상시험 분석
• 임상시험 분석 : 연구 유형별 분석
• 임상시험 분석 : 상태별 분석
• 임상시험 분석 : 단계별 분석
• 중요 포인트
• 특허 분석
• 중요 포인트

제6장 시장 세분화 분석

• 세분화 내역
• 세계 종양 분야 단클론항체 시장 : 유형별
• 중요 포인트
• 인간화
• 인간
• 키메라
• 세계 종양 분야 단클론항체 시장 : 암 유형별
• 중요 포인트
• 폐암
• 유방암
• 대장암
• 림프종
• 백혈병
• 흑색종
• 다발성 골수종
• 기타 암
• 지리적 분류
• 세계 종양 분야 단클론항체 시장 : 지역별
• 중요 포인트
• 북미
• 유럽
• 아시아태평양
• 남미
• 중동 및 아프리카

제7장 경쟁 정보

• 중요 포인트
• 경쟁 상황
• 기업 점유율 분석

제8장 세계 종양 분야 단클론항체 시장의 지속가능성 : ESG 관점

• ESG : 소개
• 세계 종양 분야 단클론항체 시장의 지속가능성
• ESG 관점
• 환경에 미치는 영향
• 사회에 미치는 영향
• 거버넌스의 영향
• ESG 리스크 평가
• 결론

제9장 부록

• 조사 방법
• 약어
• 출처
• 기업 소개
• ABBVIE INC.
• AMGEN INC.
• ASTRAZENECA
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• GILEAD SCIENCES INC.
• GSK PLC
• JAZZ PHARMACEUTICALS INC.
• JOHNSON & JOHNSON
• LILLY USA LLC.
• MERCK & CO. INC.
• PFIZER INC.
• REGENERON PHARMACEUTICALS INC.
• SANOFI
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• 스타트업/시장 교란자

영문목차

The global market for monoclonal antibodies in oncology is expected to grow from $129.3 billion in 2025 and is projected to reach $228 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12% during the forecast period of 2025 to 2030.

The North American market for monoclonal antibodies in oncology is expected to grow from $74.5 billion in 2025 and is projected to reach $132.2 billion by the end of 2030, at a CAGR of 12.2% during the forecast period of 2025 to 2030.

The European market for monoclonal antibodies in oncology is expected to grow from $29.2 billion in 2025 and is projected to reach $50.7 billion by the end of 2030, at a CAGR of 11.7% during the forecast period of 2025 to 2030.

Report Scope

The report provides detailed information on monoclonal antibodies in oncology. This report analyzes the market trends and includes global revenue ($ million) for the base year 2024, estimated data for 2025, and forecast data from 2025 through 2030. The report highlights the current and future market potential of monoclonal antibodies in oncology and provides a detailed analysis of the competitive environment. It includes regulatory scenarios, drivers, restraints and opportunities, as well as market projections for 2030 and the market share for key companies.

The market scope in this report is segmented by type, cancer type and region. By type, the market is segmented into humanized, human and chimeric. The cancer type segment is characterized into lung cancer, breast cancer, colorectal cancer, lymphoma, leukemia, melanoma, multiple myeloma and other cancers.

The region covered in this study includes North America, Europe, Asia-Pacific, the Middle East and Africa (MEA) and South America. The regional segment provides a detailed analysis of major countries, including the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China, South Korea, Australia and India.

The report aims to:

• Analyze types of monoclonal antibodies in oncology.
• Analyze global market size and segmentation.
• Understand market constraints and drivers.
• Provide detailed market forecasts through 2030.
• Assess market shares, competitiveness and industry structure.
• Identify potential long-term impacts on the market for monoclonal antibodies in oncology.

Report Includes

• 91 data tables and 59 additional tables
• In-depth analysis of the global markets for monoclonal antibodies (mAbs) for oncology
• Analyses of the global market trends, with historic revenue (sales data) from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
• Estimates of the current market size and revenue prospects for the global market, along with a corresponding market share analysis based on type, cancer type and region
• Facts and figures about market dynamics, opportunities and deterrents, technological advances, regulations, prospects and the impact of macroeconomic variables
• Highlights of promising new advancements in monoclonal antibody-based nanoparticle therapy in cancer treatment, the emergence of next-generation therapeutic inhibitors, their potential and mechanism of action
• Insights derived from Porter's Five Forces model, as well as global supply chain analyses
• Review of the regulatory landscape featuring the U.S. premarket notifications and approvals with emphasis on recently approved products as well as products under development or in different stages of clinical trials
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
• A relevant patent analysis, featuring key granted and published patents
• Analysis of the industry structure, including companies' market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
• Profiles of the leading companies, including Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Co., Johnson & Johnson Services, AstraZeneca, and Amgen Inc.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Dynamics and Growth Factors
• Emerging Technologies
• Segmental Analysis
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Overview
• Macroeconomic Factors Analysis
• Impact of U.S. Tariffs on the Pharmaceutical Industry
• Healthcare Expenditure
• Aging Population
• Geopolitical Risks, Trade Wars and Supply Chain Disruptions
• Impact of Global Economic Growth (GDP) on the Pharmaceutical Sector
• Porter's Five Forces Analysis
• Bargaining Power of Buyers
• Bargaining Power of Suppliers
• Potential for New Entrants
• Threat of Substitutes
• Competitiveness in the Industry

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Acceleration in Cancer Rates
• Unmet Treatment Need and the Role of Monoclonal Antibodies in Oncology
• Increasing R&D Spending by Companies
• Rise in Government Funding and Pharmaceutical R&D Spending
• Market Restraints
• High Cost of Monoclonal Antibodies
• Loss of Exclusivity and Genericization
• Shortage of Oncology Professionals
• Market Opportunities
• Potential of Monoclonal Antibodies in Oncology
• Emerging Markets

Chapter 4 Regulatory Landscape

• Overview
• U.S.
• Europe
• Asia-Pacific

Chapter 5 Emerging Technologies, Clinical Trial Analysis and Patent Analysis

• Overview
• Artificial Intelligence (AI)
• Immunotherapy and Cell Therapy
• Emergent Biomarkers
• Clinical Trial Analysis
• Clinical Trials Analysis by Type of Study
• Clinical Trials Analysis by Status
• Clinical Trials Analysis by Phase
• Key Takeaways
• Patent Analysis
• Key Takeaways

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Global Market for Monoclonal Antibodies in Oncology, by Type
• Key Takeaways
• Humanized
• Human
• Chimeric
• Global Market for Monoclonal Antibodies in Oncology, by Cancer Type
• Key Takeaways
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Lymphoma
• Leukemia
• Melanoma
• Multiple Myeloma
• Other Cancers
• Geographic Breakdown
• Global Market for Monoclonal Antibodies in Oncology, by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• South America
• Middle East and Africa

Chapter 7 Competitive Intelligence

• Key Takeaways
• Competitive Landscape
• Company Share Analysis

Chapter 8 Sustainability in the Global Market for Monoclonal Antibodies in Oncology: An ESG Perspective

• Introduction to ESG
• Sustainability in the Global Market for Monoclonal Antibodies in Oncology
• ESG Perspective
• Environmental Impact
• Social Impact
• Governance Impact
• ESG Risk Ratings
• Conclusion

Chapter 9 Appendix

• Methodology
• Abbreviations
• Sources
• Company Profiles
• ABBVIE INC.
• AMGEN INC.
• ASTRAZENECA
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• GILEAD SCIENCES INC.
• GSK PLC
• JAZZ PHARMACEUTICALS INC.
• JOHNSON & JOHNSON
• LILLY USA LLC.
• MERCK & CO. INC.
• PFIZER INC.
• REGENERON PHARMACEUTICALS INC.
• SANOFI
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• Emerging Companies/Market Disruptors